Evidence map›Paper›PMID 35447596›Full record

ArticleBiosensors & bioelectronics2022

Measurements of SARS-CoV-2 antibody dissociation rate constant by chaotrope-free biolayer interferometry in serum of COVID-19 convalescent patients.

Ying Hao, He S Yang, Mohsen Karbaschi, Sabrina E Racine-Brzostek, Pu Li, Robert Zuk, Yawei J Yang, P J Klasse, Yuanyuan Shi, Zhen Zhao

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biosensors & bioelectronics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Ying HaoDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA; School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China. Electronic address: yih4001@med.cornell.edu.
He S YangDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA; NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, USA.
Mohsen KarbaschiGator Bio, Palo Alto, CA, USA.
Sabrina E Racine-BrzostekDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA; NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, USA.
Pu LiGator Bio, Palo Alto, CA, USA.
Robert ZukGator Bio, Palo Alto, CA, USA.
Yawei J YangDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA; NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, USA.
P J KlasseDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, USA.
Yuanyuan ShiSchool of Life Sciences, Beijing University of Chinese Medicine, Beijing, China; Shenzhen Research Institute, Beijing University of Chinese Medicine, Shenzhen, Guangdong, China. Electronic address: yshi@bucm.edu.cn.
Zhen ZhaoDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA; NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, USA. Electronic address: zhz9010@med.cornell.edu.
NewYork–Presbyterian Hospital · USBeijing University of Chinese Medicine · CNCornell University · US

Funding

NEUTRALIZATION OF PRIMARY HIV1 VIRUSESR37AI036082 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOORE, JOHN P · 1998 to 2017
$7.0M
Neutralization of Primate Immunodeficiency VirusesR01AI036082 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JOHN P MOORE · 1994 to 2026
$4.3M
NIAID NIH HHS R01 AI036082NIAID NIH HHS R37 AI036082
6 · The paper itself

Abstract

Kinetics measurements of antigen-antibody binding interactions are critical to understanding the functional efficiency of SARS-CoV-2 antibodies. Previously reported chaotrope-based avidity assays that rely on artificial disruption of binding do not reflect the natural binding kinetics. This study developed a chaotrope- and label-free biolayer interferometry (BLI) assay for the real-time monitoring of receptor binding domain (RBD) binding kinetics with SARS-CoV-2 spike protein in convalescent COVID-19 patients. An improved conjugation biosensor probe coated with streptavidin-polysaccharide (SA-PS) led to a six-fold increase of signal intensities and two-fold reduction of non-specific binding (NSB) compared to streptavidin only probe. Furthermore, by utilizing a separate reference probe and biotin-human serum albumin (B-HSA) blocking process to subtracted NSB signal in serum, this BLI biosensor can measure a wide range of the dissociation rate constant (k

Indexed as

Biosensing TechniquesCOVID-19AdolescentAdultAntibodies, NeutralizingAntibodies, ViralChildHumansImmunologic TechniquesInterferometrySARS-CoV-2Spike Glycoprotein, CoronavirusStreptavidinAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2StreptavidinAvidityBiolayer interferometryCOVID-19Dissociation rate constantKineticsSARS-CoV-2

Identifiers

PMID35447596
PMCPMC8993703
OpenAlexW4224326982

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.